title: Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066.
abstract: CGS 26303 has previously been shown to inhibit human endothelin converting enzyme-1 (ECE-1) with an IC50 of 410 nM and to be efficacious in several animal disease models. However, it is a more potent inhibitor of neutral endopeptidase 24.11 (NEP) with an IC50 of 1 nM. The aim of this study was to optimize CGS 26303 for greater potency and selectivity towards ECE-1 inhibition. The in vivo activity of the compounds was assessed by inhibition of the big endothelin-1 (ET-1)-induced pressor response in anesthetized rats at 90 min after treatment with a dose of 10 mg/kg, i.v. Under these conditions, CGS 26303 inhibited the pressor response to big ET-1 by 50%. Replacement of the biphenyl and tetrazol groups in CGS 26303 with a dibenzofuran and carboxylic acid, respectively, yielded CGS 35066, a potent ECE-1 inhibitor having an IC50 of 22 nM. In contrast, these substitutions markedly weakened the NEP inhibitory activity of the compound to an IC50 of 2.3 microM. CGS 35066 also exhibited a potent and sustained ECE-1 inhibitory activity in vivo, blocking the pressor response to big ET-1 by 84%. Its orally active prodrug, CGS 35339, was obtained by introducing two phenyl groups at the phosphonic acid substituent in CGS 35066. Therefore, CGS 35066 and CGS 35339 represent novel compounds for assessing the pathogenic role of ET-1 overproduction in various disease states.
authors.affiliation: Metabolic and Cardiovascular Diseases Research, Novartis Institute for Biomedical Research, Summit, New Jersey, USA.
authors.forename: A Y
authors.initials: AY
authors.lastname: Jeng
authors.forename: S
authors.initials: S
authors.lastname: De Lombaert
authors.forename: M E
authors.initials: ME
authors.lastname: Beil
authors.forename: C W
authors.initials: CW
authors.lastname: Bruseo
authors.forename: P
authors.initials: P
authors.lastname: Savage
authors.forename: M
authors.initials: M
authors.lastname: Chou
authors.forename: A J
authors.initials: AJ
authors.lastname: Trapani
mesh_terms: D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors*; D001572:Benzofurans / Q000138:chemical synthesis / Q000494:pharmacology*; D019556:COS Cells; D015195:Drug Design; D000072396:Endothelin-Converting Enzymes; D006801:Humans; D008666:Metalloendopeptidases; D063065:Organophosphonates / Q000138:chemical synthesis / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000494:pharmacology*; D051381:Rats; D013329:Structure-Activity Relationship
chemical_list: D001572:Benzofurans; C404932:CGS 35066; D063065:Organophosphonates; D011480:Protease Inhibitors; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; C000606923:ECE1 protein, human; D000072396:Endothelin-Converting Enzymes